NCT02932137

Anti-infection of Low-does IL-2 in SLE

Potential Effect of Anti-infection by Low-dose IL-2 in Treatment of SLE

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The objective of this clinical study is to evaluate the potential effect of anti-infection of low-does IL-2 in patients with SLE.

Detailed description

Systemic lupus erythematosus (SLE) is a chronic autoimmune syndrome affecting various organs.Many feel that glucocorticoid and immunosuppressor are the standard therapy for patients with SLE. While it can improve the risk of infection among SLE patients. A novel therapy to treat SLE with low-does IL-2 has been identified recently. IL-2 also used to against some virus infect. So we hypothesized that low-dose IL-2 could reduce risk of infection in SLE patients. Methods: A total of SLE patients (n=30) were divided into two groups randomly. One received standard therapy, while another one administrate with low-does IL-2 plus standard therapy.Each patient will be treated with low-dose IL-2. The end points are clinical and immunologic response. Expected Results: This trail wlii provide both clinical and basic profe that low-dose IL-2 plus standard therapy have lower infection risk in SLE patients.

Conditions

• Systemic Lupus Erythematosus

Interventions

Type	Name	Description
DRUG	Interleukin-2	Patients receive low dose recombinant human Interleukin-2（HrIL-2）

Timeline

• Start date: 2016-05-05
• Primary completion: 2016-12-16
• Completion: 2017-08-30
• First posted: 2016-10-13
• Last updated: 2018-03-15

Locations

1 site across 1 country: China